Neuropsychiatric sequelae of pharmacotherapy of cardiac arrhythmias and hypertension.
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001921:Brain / Q000187:drug effects*; D004347:Drug Interactions; D006145:Guanethidine / Q000009:adverse effects; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects; D006973:Hypertension / Q000188:drug therapy*; D008012:Lidocaine / Q000009:adverse effects; D008750:Methyldopa / Q000009:adverse effects; D011342:Procainamide / Q000009:adverse effects; D011619:Psychotropic Drugs / Q000008:administration & dosage; D011802:Quinidine / Q000009:adverse effects; D012640:Seizures / Q000139:chemically induced
D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D011619:Psychotropic Drugs; D006830:Hydralazine; D008750:Methyldopa; D008012:Lidocaine; D011802:Quinidine; D011342:Procainamide; D006145:Guanethidine